Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Endocyte Secures $15 Million in Series C-3 Round of Financing
April 11th, 2007
Endocyte Inc., a biotechnology company developing receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases, announced Friday (March 23) that it has completed a $15.0 million Series C-3 financing. Along with cash remaining from the previous financing, these funds will support the development of Endocyte's folate-targeted cancer therapies including three phase 2 clinical studies and one phase 1 study. The studies will target cancers including renal cell carcinoma, ovarian cancer and non-small cell lung cancer. Endocyte also will continue its development efforts related to autoimmune therapies and extend its pipeline with next-generation oncology...
Source: Immunotherapy Weekly (2007-04-11)
|
